Clinical Scorecard: The Role of Resveratrol in Modulating Neuroinflammation in Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, and Cerebral Ischemia

At a Glance

Key Highlights

• Resveratrol exhibits antioxidant, anti-inflammatory, and neuroprotective properties.
• It can modulate biological pathways associated with neurodegeneration.
• Preclinical studies show improvements in cognitive performance and reduction of neuroinflammatory markers.
• Clinical data on resveratrol's efficacy remain limited and require further investigation, particularly regarding safety.
• Challenges include low bioavailability and variability in dosing regimens, which must be addressed in clinical applications.

Guideline-Based Recommendations

Diagnosis

• Consider neuroinflammatory biomarkers in the assessment of neurological disorders.

Management

• Explore resveratrol as a potential adjunct therapy in neurodegenerative diseases, addressing bioavailability challenges.

Monitoring & Follow-up

• Monitor cognitive performance and neuroinflammatory markers in patients receiving resveratrol.

Risks

• Be aware of the low bioavailability of resveratrol and its implications for clinical use.

Patient & Prescribing Data

Further clinical studies are needed to establish effective dosing, therapeutic relevance, and address bioavailability issues.

Clinical Best Practices

• Integrate findings from experimental and clinical research to inform treatment strategies.
• Consider the role of resveratrol in modulating key pathways involved in neuroinflammation.
• Implement patient monitoring strategies for cognitive performance and neuroinflammatory markers.

References

• PubMed
• Scopus
• Web of Science